Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 5/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24896779 | 1.00 | PTGDR2 (0.34) | PTGDR2CXCR2MAPKAPK2RORCNAMPT | |
| SCHEMBL30362248 | 0.87 | PTGDR2 (0.38) | PTGDR2MAPKAPK2RORCNAMPTAAK1 | |
| SCHEMBL25251320 | 0.87 | PTGDR2 (0.38) | PTGDR2MAPKAPK2RORCNAMPTAAK1 | |
| SCHEMBL26453252 | 0.85 | PTGDR2 (0.36) | PTGDR2MAPKAPK2RORCNAMPTBRD4 | |
| SCHEMBL30192499 | 0.84 | PTGDR2 (0.36) | PTGDR2MAPKAPK2RORCNAMPTBRD4 | |
| SCHEMBL30919455 | 0.84 | PTGDR2 (0.36) | PTGDR2MAPKAPK2RORCNAMPTBRD4 | |
| SCHEMBL24896789 | 0.84 | PTGDR2 (0.36) | PTGDR2MAPKAPK2RORCNAMPTBRD4 | |
| SCHEMBL25350925 | 0.80 | NAMPT (0.35) | PTGDR2MAPKAPK2RORCNAMPTAAK1 | |
| SCHEMBL30362262 | 0.80 | NAMPT (0.35) | PTGDR2MAPKAPK2RORCNAMPTAAK1 | |
| SCHEMBL25254861 | 0.79 | MAPKAPK2 (0.36) | PTGDR2MAPKAPK2NAMPTAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421211-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240368117-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2023285497-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | PTGDR2 1206/4885CXCR2 121/4885MAPKAPK2 4701/4885 |
| US-12421211-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | PTGDR2 1206/4885CXCR2 121/4885MAPKAPK2 4701/4885 |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | F12, PM20D2, XDH | PTGDR2 1349/4885CXCR2 93/4885MAPKAPK2 4682/4885 |
| US-20240368117-A1 | HETEROCYCLIC COMPOUNDS | F12, C1R, MRPL21 | PTGDR2 1206/4885CXCR2 121/4885MAPKAPK2 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.